Acadian Asset Management LLC Has $12.87 Million Stake in DexCom, Inc. $DXCM

Key Points

• Acadian Asset Management LLC significantly increased its stake in DexCom, Inc. by 275.1% during the first quarter, owning 188,628 shares valued at approximately $12.87 million.
• Analyst ratings for DexCom vary, with Oppenheimer lowering its rating to "market perform," while Canaccord Genuity reissued a "buy" rating with a price target of $106.00.
• DexCom reported a quarterly revenue of $1.16 billion, surpassing analysts' expectations, and showed a year-over-year earnings per share increase from $0.43 to $0.48.

Acadian Asset Management LLC raised its position in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 275.1% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 188,628 shares of the medical device company's stock after buying an additional 138,335 shares during the period. Acadian Asset Management LLC's holdings in DexCom were worth $12,870,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of DXCM. Golden State Wealth Management LLC increased its holdings in shares of DexCom by 211.2% during the first quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company's stock worth $27,000 after buying an additional 264 shares in the last quarter. Zions Bancorporation National Association UT acquired a new stake in shares of DexCom during the first quarter worth approximately $27,000. Heck Capital Advisors LLC acquired a new stake in shares of DexCom during the fourth quarter worth approximately $38,000. Alpine Bank Wealth Management acquired a new stake in shares of DexCom during the first quarter worth approximately $40,000. Finally, Private Trust Co. NA increased its holdings in shares of DexCom by 99.4% during the first quarter. Private Trust Co. NA now owns 672 shares of the medical device company's stock worth $46,000 after buying an additional 335 shares in the last quarter. Institutional investors and hedge funds own 97.75% of the company's stock.

Analyst Ratings Changes

Several research firms have recently weighed in on DXCM. Oppenheimer lowered shares of DexCom from an "outperform" rating to a "market perform" rating in a report on Monday. Canaccord Genuity Group reissued a "buy" rating and set a $106.00 price target on shares of DexCom in a research note on Friday, August 1st. Argus started coverage on shares of DexCom in a research note on Thursday, August 21st. They set a "buy" rating and a $100.00 price target on the stock. Wall Street Zen cut shares of DexCom from a "strong-buy" rating to a "buy" rating in a research note on Sunday, August 10th. Finally, Barclays increased their price target on shares of DexCom from $93.00 to $98.00 and gave the company an "equal weight" rating in a research note on Wednesday, July 30th. Three research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and five have issued a Hold rating to the company's stock. According to MarketBeat, DexCom presently has a consensus rating of "Moderate Buy" and a consensus target price of $99.89.

Insider Activity

In other DexCom news, Director Mark G. Foletta sold 2,750 shares of DexCom stock in a transaction on Friday, August 15th. The shares were sold at an average price of $81.06, for a total transaction of $222,915.00. Following the completion of the sale, the director owned 51,121 shares of the company's stock, valued at approximately $4,143,868.26. The trade was a 5.10% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Nicholas Augustinos sold 3,672 shares of DexCom stock in a transaction on Monday, June 16th. The stock was sold at an average price of $82.80, for a total transaction of $304,041.60. Following the sale, the director directly owned 33,411 shares of the company's stock, valued at $2,766,430.80. This represents a 9.90% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 15,237 shares of company stock worth $1,263,480. Corporate insiders own 0.32% of the company's stock.

DexCom Price Performance

DXCM opened at $76.00 on Friday. The company has a fifty day moving average price of $81.01 and a two-hundred day moving average price of $78.80. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.35 and a current ratio of 1.52. DexCom, Inc. has a 52 week low of $57.52 and a 52 week high of $93.25. The firm has a market capitalization of $29.80 billion, a PE ratio of 52.78, a P/E/G ratio of 1.59 and a beta of 1.48.

DexCom (NASDAQ:DXCM - Get Free Report) last released its earnings results on Wednesday, July 30th. The medical device company reported $0.48 EPS for the quarter, topping analysts' consensus estimates of $0.45 by $0.03. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The firm had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.13 billion. During the same quarter in the previous year, the business earned $0.43 EPS. The business's quarterly revenue was up 15.2% compared to the same quarter last year. DexCom has set its FY 2025 guidance at EPS. As a group, analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.